Based on 17 Wall Street analysts offering 12 month price targets for Sarepta Therapeutics in the last 3 months. The average price target is $168.35 with a high forecast of $224.00 and a low forecast of $128.00. The average price target represents a 28.14% change from the last price of $131.38.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"77":"$77","114":"$114","151":"$151","188":"$188","225":"$225"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":224,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$224.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":168.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$168.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":128,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$128.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[77,114,151,188,225],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2023","6":"Nov<br/>2023","9":"Feb<br/>2024","12":"May<br/>2024","25":"May<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.66,140.60923076923078,147.55846153846153,154.5076923076923,161.4569230769231,168.40615384615384,175.35538461538462,182.30461538461537,189.25384615384615,196.20307692307694,203.1523076923077,210.10153846153847,217.05076923076922,{"y":224,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.66,136.32846153846154,138.99692307692308,141.6653846153846,144.33384615384614,147.00230769230768,149.67076923076922,152.33923076923077,155.0076923076923,157.67615384615385,160.3446153846154,163.0130769230769,165.68153846153845,{"y":168.35,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,133.66,133.2246153846154,132.78923076923076,132.35384615384615,131.91846153846154,131.4830769230769,131.0476923076923,130.6123076923077,130.1769230769231,129.74153846153845,129.30615384615385,128.87076923076924,128.4353846153846,{"y":128,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":110.1,"date":1683849600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.16,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":109,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.31,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":122.51,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.94,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.44,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.34,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.27,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":128.67,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":126.08,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.66,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$224.00

Average Price Target$168.35

Lowest Price Target$128.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Mizuho Securities

xxxxxxxxxxxxx

Reiterated

05/15/24

xxxxxxxxxxxxxxxxxx

Oppenheimer

xxxxxxxxxxxxx

Upgraded

05/14/24

xxxxxxxxxxxxxxxxxx

Morgan Stanley

xxxxxxxxxxxxx

Reiterated

05/06/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Assigned

05/03/24

xxxxxxxxxxxxxxxxxx

Barclays

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

05/02/24

xxxxxxxxxxxxxxxxxx

BMO Capital

xxxxxxxxxxxxx

Assigned

05/02/24

xxxxxxxxxxxxxxxxxx

Cantor Fitzgerald

xxxxxxxxxxxxx

Reiterated

05/01/24

xxxxxxxxxxxxxxxxxx

RBC Capital

xxxxxxxxxxxxx

Assigned

05/01/24

Joseph Schwartz

Leerink Partners

$165.00

Buy

25.59%

Upside

Reiterated

05/01/24

Brian Skorney

Robert W. Baird

$170.00

Buy

29.40%

Upside

Reiterated

05/01/24

We think the potential for early action bodes well for the company to receive a broad label, inclusive of all ambulatory patients, and potentially even capturing non-ambulatory patients. We see significant near term upside into a broader label as we believe it would significantly ramp up Elevidys sales well into blockbuster territory.

David Hoang

Citi

$172.00

Buy

30.92%

Upside

Reiterated

05/01/24

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (NYSE: NVO), Sarepta Therapeutics (NASDAQ: SRPT) and Acadia Healthcare (NASDAQ: ACHC)

Ritu Baral

TD Cowen

$165.00

Buy

25.59%

Upside

Assigned

02/29/24

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT) and Immunocore Holdings (NASDAQ: IMCR)

Andreas Argyrides

Wedbush

$224.00

Buy

70.50%

Upside

Assigned

02/29/24

Sarepta Therapeutics: A Strong Buy on Robust Financials and Promising Drug Pipeline Prospects

Best Analysts Covering Sarepta Therapeutics

Which Analyst Should I Follow If I Want to Buy SRPT and Sell After:

1 Month

Brian SkorneyRobert W. Baird

Success Rate

32/46 ratings generated profit

Average Return

+3.61%

reiterated a buy rating 17 days ago

Copying Brian Skorney's trades and holding each position for 1 Month would result in 69.57% of your transactions generating a profit, with an average return of +3.61% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Hartaj SinghOppenheimer

Success Rate

14/21 ratings generated profit

Average Return

+11.28%

upgraded a buy rating 4 days ago

Copying Hartaj Singh's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +11.28% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Joseph SchwartzLeerink Partners

Success Rate

21/25 ratings generated profit

Average Return

+24.47%

reiterated a buy rating 17 days ago

Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 84.00% of your transactions generating a profit, with an average return of +24.47% per trade.

2 Years

Joseph SchwartzLeerink Partners

Success Rate

22/25 ratings generated profit

Average Return

+28.47%

reiterated a buy rating 17 days ago

Copying Joseph Schwartz's trades and holding each position for 2 Years would result in 88.00% of your transactions generating a profit, with an average return of +28.47% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SRPT Analyst Recommendation Trends

Rating

Jan 24

Feb 24

Mar 24

Apr 24

May 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SRPT has received 24 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. SRPT average Analyst price target in the past 3 months is $168.35.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

SRPT Financial Forecast

SRPT Earnings Forecast

Next quarter’s earnings estimate for SRPT is -$0.10 with a range of -$0.43 to $0.27. The previous quarter’s EPS was $0.37. SRPT beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year SRPT has Outperformed its overall industry.

SRPT Sales Forecast

Next quarter’s sales forecast for SRPT is $385.37M with a range of $362.00M to $463.00M. The previous quarter’s sales results were $413.46M. SRPT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.17% of the time in the same period. In the last calendar year SRPT has Outperformed its overall industry.

SRPT Stock Forecast FAQ

What is SRPT’s average 12-month price target, according to analysts?

Based on analyst ratings, Sarepta Therapeutics’s 12-month average price target is $168.35.

What is SRPT’s upside potential, based on the analysts’ average price target?

Sarepta Therapeutics has 28.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SRPT a Buy, Sell or Hold?

Sarepta Therapeutics has a conensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.

What is Sarepta Therapeutics’s price target?

The average price target for Sarepta Therapeutics is $168.35. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $224.00 ,the lowest forecast is $128.00. The average price target represents 28.14% Increase from the current price of $131.38.

What do analysts say about Sarepta Therapeutics?

Sarepta Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of SRPT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

SRPT Analyst Ratings

SRPT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sarepta Therapeutics

SRPT Analyst Recommendation Trends

SRPT Financial Forecast

SRPT Earnings Forecast

SRPT Sales Forecast

SRPT Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts